Skip to main content
. 2022 Mar 28;27(Suppl 1):S5–S6. doi: 10.1093/oncolo/oyac013

Table 2.

Overall and progression-free survival in HER2-positive metastatic breast cancer

Endpoint Pyrotinib plus capecitabine(n = 134) Lapatinib plus capecitabine(n = 132) HR(95% CI) p value
Median OS Not reached 26.9 months 0.69 (0.48-0.98) .02
Median PFS 5.6 months 12.5 months 0.48 (0.37-0.63) <.0001